An observational study in COVID-19, Renal Replacement Therapy and Acute Kidney Injury, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-07-29.
Sponsored by University Hospital, Montpellier · Observational
Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 100 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.
Counted across the registry records on this site, refreshed daily.
COVID-19 patients admitted to the Montpellier University Hospital with at least one rine sample drawn
Exclusion criteria:
COVID-19 patients with urinary samples
Other: [TIMP-2]*[IGFBP-7]
\[TIMP-2\]\*\[IGFBP-7\] mesurement in urine sample relicates of COVID-19 patients admitted to the Montpellier University Hospital
Sensibility and specificity of urinary
Sensibility and specificity of urinary \[TIMP-2\]\*\[IGFBP-7\] \> 0,3 to predict AKI (KDIGO stage ≥ 1) in SARS-CoV-2 patients at day-7 after measurement
Time frame: Occurence of AKI 7 days after urinary biomarkers measurement
Sensibility and specificity of urinary
Sensibility and specificity of urinary \[TIMP-2\]\*\[IGFBP-7\] \> 0,3 to predict AKI worsening, renal replacement therapy requirement or persistant AKI
Time frame: Occurnce of AKI worsening, renal replacement therapy requirement or persistant AKI, 7 days after urinary biomarkers mesurement
Plan to share: Undecided — NC
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier